Skip to main content
CELADON PHARMACEUTICALS PLC logo

CELADON PHARMACEUTICALS PLC — Investor Relations & Filings

Ticker · CEL ISIN · GB00BDQYGP38 LEI · 213800YXCATORT475807 IL Manufacturing
Open in API
Filings indexed 128 across all filing types
Latest filing 2023-10-13 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL CEL

About CELADON PHARMACEUTICALS PLC

https://celadonpharma.co.uk/

Celadon Pharmaceuticals PLC is a vertically integrated pharmaceutical company focused on the research, cultivation, manufacturing, and supply of cannabinoid-based medicines. The company operates a licensed, 100,000 sq ft facility with EU-GMP certification for the indoor, hydroponic cultivation of high-THC cannabis and the extraction of cannabinoid Active Pharmaceutical Ingredients (API). Its primary focus is the chronic pain market, and it is conducting an MHRA conditionally approved clinical trial to generate data supporting the use of its medicines for this condition. Additionally, Celadon has an in-house research and development program focused on intellectual property generation and is involved in developing a licensed cannabinoid treatment for Autism Spectrum Disorder through a biopharma partnership.

Recent filings

Filing Released Lang Actions
Fundraise, CLN Issue, Joint Broker Appointed & TVR
Share Issue/Capital Change Classification · 99% confidence The document is identified by the RNS Number header and the explicit mention of 'RNS Number : 9906P' and 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS). The content details a 'Fundraise' (£1.0m placing and subscription), the appointment of a Joint Broker, plans for future Convertible Loan Notes, and an update on 'Total Voting Rights'. These are typical corporate actions announced via RNS. Since the document is an announcement of corporate actions (fundraising, broker appointment, voting rights update) and is explicitly branded as an RNS release, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such official regulatory dissemination that doesn't fit a more specific category like DIV, CAP, or DIRS, although it contains elements of capital raising (CAP). Given the context of the RNS distribution system and the nature of the announcement as a broad update, RNS is the best fit, especially as it is not a full financial report (10-K, IR) or a specific proxy/remuneration document.
2023-10-13 English
Interim Results
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Interim results for the six months ended 30 June 2023' for Celadon Pharmaceuticals plc. It contains detailed financial highlights (revenue, operating loss, cash balance), a CEO's report, and operational updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2023
2023-09-28 English
Notice of Results and Investor Presentation
Regulatory Filings Classification · 99% confidence The document is a formal announcement disseminated via RNS (RNS Number : 7427M) from Celadon Pharmaceuticals PLC. The title is "Notice of Results and Investor Presentation." The text explicitly states that the company "will announce its results for the six months ended 30 June 2023 on Thursday 28 September 2023." It then details the schedule for an Analyst Briefing and a separate Investor Presentation, including Q&A sessions. This document is not the results themselves (ER or IR), nor is it the full presentation (IP). It is an announcement *about* the upcoming release of results and the hosting of presentations/briefings. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports/events. Since it specifically announces the timing of the results release and subsequent investor/analyst events, RPA is the most precise fit, although RNS is also applicable as a general regulatory filing. Given the specific nature of announcing the timing of results and associated events, RPA is preferred over the general RNS fallback.
2023-09-18 English
New Sales Contract with UK Pharmaceutical Company
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and is dated '05 September 2023'. It announces a 'New Sales Contract' and provides details about the contract terms and expected revenue. The closing section explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and source identification strongly indicate a general regulatory announcement disseminated via the RNS system, which corresponds to the 'Regulatory Filings' category (RNS), as it is not a specific financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA).
2023-09-05 English
Approval to roll-out chronic pain clinical trial
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 7869H' and is dated '01 August 2023'. It contains standard regulatory boilerplate language at the end, mentioning 'RNS, the news service of the London Stock Exchange' and 'Market Abuse Regulation (EU) 596/2014'. The content is an announcement regarding the approval to roll out a clinical trial, which is a material event disclosure. Since it is a general regulatory announcement distributed via the RNS system and does not fit neatly into specific categories like ER, 10-K, or DIV, the most appropriate classification is the general regulatory filing category.
2023-08-01 English
Group of companies' accounts made up to 2022-12-31
Regulatory Filings
2023-07-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.